Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Urogen Pharma reported a quarterly loss of $0.55 per share, better than the Zacks Consensus Estimate of a loss of $0.84, and an improvement from a loss of $0.68 per share a year ago, representing an earnings surprise of 34.52% [1] - The company posted revenues of $25.2 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.06%, compared to year-ago revenues of $20.85 million [2] - Over the last four quarters, Urogen Pharma has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Stock Performance - Urogen Pharma shares have declined approximately 18.6% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current estimate revisions trend for Urogen Pharma is unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.83 on revenues of $27.27 million, and for the current fiscal year, it is -$3.49 on revenues of $92.1 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is currently in the top 38% of Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]